 <h1>Moxetumomab pasudotox Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to moxetumomab pasudotox: intravenous powder for solution</i></p><h3>Warning</h3><p class="blackboxWarning-title">Intravenous route (Powder for Solution)</p><p>Warning: Capillary Leak Syndrome And Hemolytic Uremic SyndromeCapillary Leak Syndrome (CLS), including life-threatening cases, occurred in patients receiving moxetumomab pasudotox-tdfk. Monitor weight and blood pressure; check labs, including albumin, if CLS is suspected. Delay dosing or discontinue moxetumomab pasudotox-tdfk as recommended.Hemolytic Uremic Syndrome (HUS), including life-threatening cases, occurred in patients receiving moxetumomab pasudotox-tdfk. Monitor hemoglobin, platelet count, serum creatinine, and ensure adequate hydration. Discontinue moxetumomab pasudotox-tdfk in patients with HUS.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, moxetumomab pasudotox may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking moxetumomab pasudotox:</p><p>
<i>More common</i>
</p><ul>
<li>Back pain</li>
<li>black, tarry stools</li>
<li>blood in the urine</li>
<li>blurred vision</li>
<li>bone pain</li>
<li>chest pain or tightness</li>
<li>chills</li>
<li>confusion</li>
<li>cough</li>
<li>dizziness</li>
<li>drowsiness</li>
<li>dry mouth</li>
<li>fast or irregular heartbeat</li>
<li>feeling of warmth</li>
<li>fever</li>
<li>headache</li>
<li>increased or decreased urination</li>
<li>increased thirst</li>
<li>joint pain, stiffness, or swelling</li>
<li>loss of appetite</li>
<li>loss of consciousness</li>
<li>lower back, side, or stomach pain</li>
<li>mood or mental changes</li>
<li>muscle cramps in the hands, arms, feet, legs, or face</li>
<li>muscle pain</li>
<li>muscle spasms (tetany) or twitching seizures</li>
<li>nausea</li>
<li>nervousness</li>
<li>numbness and tingling around the mouth, fingertips, or feet</li>
<li>painful or difficult urination</li>
<li>pale skin</li>
<li>pinpoint red spots on the skin</li>
<li>pounding in the ears</li>
<li>redness of the face, neck, arms, and occasionally, upper chest</li>
<li>seizures</li>
<li>slow or fast heartbeat</li>
<li>sore throat</li>
<li>stomach cramps or pain</li>
<li>swelling of the face, fingers, feet, lower legs, or ankles</li>
<li>trembling</li>
<li>tremor</li>
<li>troubled breathing</li>
<li>troubled breathing with exertion</li>
<li>ulcers, sores, or white spots in the mouth</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
<li>vomiting</li>
<li>yellow eyes or skin</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Chest discomfort</li>
<li>stomach bloating</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of moxetumomab pasudotox may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Constipation</li>
<li>diarrhea</li>
<li>dry eye</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Blindness</li>
<li>bloody eye</li>
<li>burning, dry, or itching eyes</li>
<li>decreased vision</li>
<li>discharge, excessive tearing</li>
<li>discomfort, pain, or swelling of the eye or around the eye</li>
<li>redness, pain, or swelling of the eye, eyelid, or inner lining of the eyelid</li>
</ul><p>
<!-- end intravenous powder for solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to moxetumomab pasudotox: intravenous powder for injection</i></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Hemoglobin decreased (43%), neutrophil count decreased (41%), platelet count decreased (21%), anemia (21%)</p>
<p><b>Common</b> (1% to 10%): Hemolytic uremic syndrome<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Frequency not reported</b>: Immunogenicity<sup>[Ref]</sup></p><h3>Local</h3><p><b>Very common</b> (10% or more): Infusion related reactions (e.g., chills, cough, dizziness, dyspnea, feeling hot, flushing, headache, hypertension, hypotension, infusion related reaction, myalgia, nausea, pyrexia, sinus tachycardia, tachycardia, vomiting, wheezing) (50%)<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Hypoalbuminemia (64%), fluid retention (63%), electrolyte abnormalities (57%), hypocalcemia (54%), hypophosphatemia (53%), hyponatremia (41%), peripheral edema (39%), hypokalemia (25%), hypomagnesemia (21%), hyperuricemia (21%)</p>
<p><b>Common</b> (1% to 10%): Weight gain, localized edema, fluid overload, fluid retention<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Blurred vision, dry eye, cataracts, ocular discomfort and/or pain, ocular swelling/periorbital edema, conjunctivitis, conjunctival hemorrhage, ocular discharge<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): ALT increased (65%), AST increased (55%), blood bilirubin increased (30%), GGT increased (25%)<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Cough, dyspnea, wheezing</p>
<p><b>Common</b> (1% to 10%): Pleural effusion<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (34%), pyrexia (31%), alkaline phosphatase increased (20%), chills, feeling hot<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (33%), dizziness<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Renal toxicity (e.g., acute kidney injury, renal impairment, renal failure, increased serum creatinine, proteinuria) (26%)<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Capillary leak syndrome (34%), flushing, hypertension, hypotension, sinus tachycardia, tachycardia</p>
<p><b>Common</b> (1% to 10%): Pericardial effusion<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Facial edema (14%), abdominal distention (13%)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (35%), constipation (23%), diarrhea (21%), vomiting</p>
<p><b>Common</b> (1% to 10%): Ascites<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Lumoxiti (moxetumomab pasudotox)." Astra-Zeneca Pharmaceuticals, Wilmington, DE. </p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>What type of drug is Lumoxiti?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about moxetumomab pasudotox</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>Drug class: miscellaneous antineoplastics</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Moxetumomab pasudotox-tdfk Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Lumoxiti</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Hairy Cell Leukemia</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to moxetumomab pasudotox: intravenous powder for injection</i></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Hemoglobin decreased (43%), neutrophil count decreased (41%), platelet count decreased (21%), anemia (21%)</p><p><b>Common</b> (1% to 10%): Hemolytic uremic syndrome<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Frequency not reported</b>: Immunogenicity<sup>[Ref]</sup></p><h3>Local</h3><p><b>Very common</b> (10% or more): Infusion related reactions (e.g., chills, cough, dizziness, dyspnea, feeling hot, flushing, headache, hypertension, hypotension, infusion related reaction, myalgia, nausea, pyrexia, sinus tachycardia, tachycardia, vomiting, wheezing) (50%)<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Hypoalbuminemia (64%), fluid retention (63%), electrolyte abnormalities (57%), hypocalcemia (54%), hypophosphatemia (53%), hyponatremia (41%), peripheral edema (39%), hypokalemia (25%), hypomagnesemia (21%), hyperuricemia (21%)</p><p><b>Common</b> (1% to 10%): Weight gain, localized edema, fluid overload, fluid retention<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Blurred vision, dry eye, cataracts, ocular discomfort and/or pain, ocular swelling/periorbital edema, conjunctivitis, conjunctival hemorrhage, ocular discharge<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): ALT increased (65%), AST increased (55%), blood bilirubin increased (30%), GGT increased (25%)<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Cough, dyspnea, wheezing</p><p><b>Common</b> (1% to 10%): Pleural effusion<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (34%), pyrexia (31%), alkaline phosphatase increased (20%), chills, feeling hot<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (33%), dizziness<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Renal toxicity (e.g., acute kidney injury, renal impairment, renal failure, increased serum creatinine, proteinuria) (26%)<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Capillary leak syndrome (34%), flushing, hypertension, hypotension, sinus tachycardia, tachycardia</p><p><b>Common</b> (1% to 10%): Pericardial effusion<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Facial edema (14%), abdominal distention (13%)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (35%), constipation (23%), diarrhea (21%), vomiting</p><p><b>Common</b> (1% to 10%): Ascites<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Lumoxiti (moxetumomab pasudotox)." Astra-Zeneca Pharmaceuticals, Wilmington, DE. </p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>What type of drug is Lumoxiti?</li>
</ul><h2>More about moxetumomab pasudotox</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>Drug class: miscellaneous antineoplastics</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Moxetumomab pasudotox-tdfk Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Hairy Cell Leukemia</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>